What Happens When You Mix Suboxone and Cocaine?

Mixing Suboxone (buprenorphine plus naloxone) with cocaine creates a pharmacologically unpredictable situation that can amplify cocaine’s effects on the brain, undermine the treatment Suboxone is meant to provide, and raise the risk of a fatal outcome. The interaction is not as straightforward as “one cancels the other out,” and the common belief that a stimulant like cocaine can safely offset an opioid’s sedation is flatly wrong. What actually happens depends on timing, dose, how long someone has been on Suboxone, and individual physiology, but none of the scenarios are good.

How Buprenorphine and Cocaine Interact in the Brain

Suboxone’s active opioid ingredient, buprenorphine, works on the brain’s opioid receptors. Cocaine works primarily by flooding the brain with dopamine, the neurotransmitter tied to pleasure and reward. These are different systems, but they overlap in a brain region called the nucleus accumbens, which is central to how we experience reward. When both drugs are present, the result is not simply additive. Early research in rats found that a low dose of buprenorphine, given alongside cocaine, boosted the peak dopamine surge in the nucleus accumbens to roughly 260% of baseline levels, compared to about 180% with cocaine alone. The researchers concluded that buprenorphine can interact with cocaine “in a synergistic manner” and may “enhance rather than attenuate the rewarding properties of cocaine.”¹

That finding runs counter to what many people assume. A person on Suboxone might expect their medication to dull the high from cocaine, but the opposite can happen, at least initially. The amplified dopamine response means the cocaine high can feel more intense during the early days of buprenorphine treatment, potentially reinforcing the desire to use cocaine again.

The Picture Changes Over Weeks

The synergistic dopamine boost does not last indefinitely. Longer-term buprenorphine treatment appears to shift the interaction. A study tracking the dopamine response over about four weeks of chronic buprenorphine treatment in rats found that the potentiated cocaine response seen in the first four to five days gradually faded over the next three weeks, even as baseline dopamine levels stayed elevated throughout treatment.² In practical terms, this suggests that someone who has been stabilized on Suboxone for weeks or months may not experience the same amplified cocaine high as someone who just started treatment. But this also does not make cocaine use safe at that point. The diminished dopamine potentiation does not mean cocaine’s cardiovascular dangers, organ strain, or overdose risk have gone away.

Cocaine Can Sabotage Suboxone Treatment

One of the less obvious consequences of using cocaine while on Suboxone is that cocaine may directly reduce how much buprenorphine reaches the bloodstream. Research has found that cocaine can significantly diminish buprenorphine concentrations in the body. The suspected mechanisms include cocaine inducing liver enzymes that break down buprenorphine faster, or cocaine’s vasoconstrictive effects reducing how much buprenorphine is absorbed through the tissues under the tongue, where the sublingual tablet dissolves.³

This matters enormously for anyone taking Suboxone to manage opioid dependence. If cocaine is lowering the effective dose of buprenorphine in your system, you are more likely to experience withdrawal symptoms, cravings for opioids, and the urge to use other opioids to fill the gap. In other words, cocaine use while on Suboxone can undermine the entire purpose of the medication, creating a vicious cycle where the person feels worse, craves more, and is at greater risk of returning to full opioid use.

The Overdose Question

A persistent and dangerous belief among people who use both opioids and stimulants is that the stimulant can counteract the opioid’s respiratory depression. The logic sounds superficially reasonable: cocaine speeds you up, opioids slow you down, so they should balance each other out. A systematic review examining the high mortality among opioid-cocaine co-users addressed this directly, calling the belief “unfounded and dangerous.”⁴

Suboxone is safer than full opioid agonists like heroin or fentanyl when it comes to respiratory depression, because buprenorphine is a partial agonist with a ceiling effect on breathing suppression. That ceiling, however, does not make combining it with cocaine safe. Cocaine places immense strain on the cardiovascular system: it spikes blood pressure, constricts blood vessels, and can trigger abnormal heart rhythms. Adding any opioid to that mix complicates the body’s ability to regulate itself. The same systematic review noted that overdose deaths from combined opioid-stimulant use are not primarily driven by a specific pharmacological interaction between the two drugs but by the cumulative burden of multiple toxic substances on the body, compounded by behavioral factors like higher-risk patterns of use among people who consume both drug types.⁴

A forensic case report illustrates the lethal potential: a fatal cocaine overdose was documented in a person who had therapeutic blood levels of buprenorphine, along with fluoxetine and cannabinoids. The death was attributed primarily to lethal cocaine concentrations, with the other substances playing a minor contributing role.⁵ Even at normal therapeutic buprenorphine levels, cocaine overdose remains fully possible.

What About the Heart?

Cocaine is already one of the most cardiotoxic recreational drugs. It can cause heart attacks, strokes, and sudden cardiac death even in young, otherwise healthy people. A reasonable concern is whether buprenorphine compounds those cardiovascular dangers. Clinical data from controlled human studies offer some reassurance on the narrow question of acute cardiovascular interaction: buprenorphine at clinical doses (4 or 8 mg per day) did not worsen the cardiovascular or respiratory changes caused by an acute dose of cocaine given intravenously in a research setting.⁶ That is worth knowing, but it comes with heavy caveats. A controlled lab setting with monitored dosing is nothing like real-world cocaine use, where the purity, dose, and route are unpredictable. And buprenorphine not making cocaine’s cardiovascular effects worse is not the same as making them safe.

How Common Is This Combination?

Cocaine use among people receiving buprenorphine treatment is far from rare. In one study of opioid-dependent patients entering buprenorphine treatment, about 39% reported using cocaine at baseline.⁷ That is not a small minority. For clinicians prescribing Suboxone, this means that a large share of their patients are potentially dealing with the pharmacological interactions and treatment-undermining effects described above, whether or not they disclose their cocaine use.

The reasons people combine the two drugs vary. Some are simply continuing pre-existing cocaine use alongside their opioid treatment. Others seek a more intense high by layering stimulant effects on top of their opioid medication. And some hold the mistaken belief that cocaine will keep them alert or counteract the sedating side of buprenorphine. All of these patterns carry risk, and all are common enough to be a significant clinical concern rather than an obscure edge case.

Can Suboxone Actually Help With Cocaine Addiction?

Paradoxically, while using cocaine alongside Suboxone is dangerous, researchers have explored whether buprenorphine-based medications could be part of a treatment for cocaine dependence itself. The reasoning comes from animal studies showing that buprenorphine can reduce compulsive cocaine self-administration, an effect that appears linked to buprenorphine’s action on kappa opioid receptors in addition to its mu receptor activity.⁸

This led to the CURB (Cocaine Use Reduction with Buprenorphine) trial, which tested whether Suboxone, given after an injection of extended-release naltrexone, could reduce cocaine use in people with cocaine dependence who also had a history of opioid problems. The results were mixed. The primary outcome measure did not reach statistical significance for either dose tested. However, a secondary analysis found that the higher dose of Suboxone was associated with reduced cocaine-positive urine samples compared to placebo.⁹ The animal research that inspired the trial had used a combination of buprenorphine and naltrexone and found that these two drugs together could block compulsive cocaine intake in rats that had developed escalated use patterns, without producing opioid dependence.⁸

This is a research avenue, not a treatment recommendation. Nobody should interpret these findings as a reason to self-medicate with Suboxone for cocaine problems. The CURB trial used a specific, clinically supervised protocol involving naltrexone injections given before Suboxone, precisely to block buprenorphine’s opioid effects while preserving whatever kappa-receptor-mediated anti-cocaine benefit it might have. That is entirely different from someone taking their regular Suboxone dose and using cocaine on top of it.

Pregnancy Adds Another Layer of Risk

For pregnant people, the stakes of combining opioids and cocaine are especially high, and not just for the mother. Suboxone (or buprenorphine alone) is commonly prescribed during pregnancy as a safer alternative to continued illicit opioid use, and it is generally considered beneficial for both mother and baby when used as directed. But adding cocaine to the equation changes the calculus dramatically.

A study examining adverse obstetrical and neonatal outcomes in women who used recreational drugs during pregnancy found that prenatal exposure to cocaine and/or opioids was associated with nearly four times higher odds of adverse neonatal outcomes compared to cannabis exposure alone.¹⁰ The neonatal harms include low birth weight, preterm delivery, and withdrawal symptoms. Cocaine’s vasoconstrictive properties restrict blood flow to the placenta, which can deprive the fetus of oxygen and nutrients. When layered on top of buprenorphine treatment, cocaine also threatens the stability of the mother’s opioid treatment through the pharmacokinetic interference described earlier, potentially triggering withdrawal episodes that themselves carry obstetric risk.

Why the “Speedball Logic” Persists

The idea that an upper and a downer cancel each other out is one of the most enduring and lethal myths in recreational drug culture. Historically, the combination of cocaine and heroin (a “speedball”) has been responsible for numerous high-profile deaths. Suboxone and cocaine is not a classic speedball because buprenorphine is only a partial opioid agonist, producing much less euphoria and respiratory depression than heroin or fentanyl. But the underlying logic people apply is the same, and it is equally flawed.

The two drugs act on different organ systems in ways that do not simply offset. Cocaine hammers the heart through stimulation of the sympathetic nervous system. Opioids suppress the respiratory drive through the brainstem. These are not opposing forces on a single dial. They are separate insults to separate systems, and the body has to cope with both simultaneously. A person whose heart is racing and whose blood pressure is dangerously elevated from cocaine does not become safer because buprenorphine is mildly slowing their breathing. They become a person in two kinds of physiological distress at once.

The motives people report for combining opioids and cocaine also include chasing a particular subjective experience: the rush of the stimulant blended with the warmth of the opioid, or using cocaine to stay awake while on Suboxone and then using Suboxone to “come down” from cocaine. These motivations, documented across studies of co-use patterns, reflect how deeply the speedball logic is embedded in drug-using communities, despite the evidence that it increases mortality rather than reducing risk.⁴

What Clinicians Watch For

Doctors prescribing Suboxone are generally aware that a substantial portion of their patients use or have recently used cocaine. Routine urine drug screens often reveal this. The clinical response is typically not to withhold Suboxone, because the benefits of opioid stabilization usually outweigh the risks of untreated opioid dependence, even in someone who is also using cocaine. An early clinical trial found that buprenorphine significantly reduced both opioid and cocaine use in patients who had been using both drugs for over a decade, suggesting that treatment engagement itself has value even when cocaine use continues at some level.⁶

Still, clinicians managing patients who use cocaine alongside Suboxone face particular challenges. They need to account for the possibility that cocaine is lowering buprenorphine levels, which might look clinically like the patient needing a dose increase or not responding to treatment. They need to monitor cardiovascular health more closely, since cocaine use adds heart risk on top of whatever baseline risk the patient carries. And they need to have frank conversations about the interaction, particularly the counterintuitive finding that buprenorphine may initially intensify cocaine’s rewarding effects, because a patient who discovers this on their own may be more likely to escalate cocaine use.

There is no approved pharmacological treatment specifically for cocaine dependence, which makes the situation harder. Unlike opioid addiction, where medications like buprenorphine and methadone have decades of evidence behind them, cocaine addiction is largely treated with behavioral interventions. The CURB trial and related research represent early steps toward changing that, but for now, the clinical toolkit for addressing cocaine use in Suboxone patients relies heavily on counseling, contingency management, and addressing the social determinants that drive ongoing drug use.